Comorbidity in social anxiety disorder: diagnostic and therapeutic challenges

Article Details

Authors
Ahmet Koyuncu MD, Ezgi İnce MD, Erhan Ertekin MD, Raşit Tükel MD

Article Type
Review

DOI
10.7573/dic.212573

Related Articles

Article Page

Abstract

Comorbid disorders are highly prevalent in patients with social anxiety disorder, occurring in as many as 90% of patients. The presence of comorbidity may affect the course of the disease in several ways such as comorbidity in patients with social anxiety disorder (SAD) is related to earlier treatment-seeking behavior, increased symptom severity, treatment resistance and decreased functioning. Moreover, comorbidities cause significant difficulties in nosology and diagnosis, and may cause treatment challenges. In this review, major psychiatric comorbidities that can be encountered over the course of SAD as well as comorbidity associated diagnostic and therapeutic challenges will be discussed.

Keywords: alcohol use disorder, anxiety, bipolar disorder, comorbidity, major depression, mood disorders, personality disorder, social anxiety disorder.

Citation: Koyuncu A, İnce E, Ertekin E, Tükel R. Comorbidity in social anxiety disorder: diagnostic and therapeutic challenges. Drugs in Context 2019; 8: 212573. DOI: 10.7573/dic.212573

Contributions: Ahmet Koyuncu contributed to the design, literature search, acquisition and interpretation of the findings, drafted the manuscript, and gave final approval. Ezgi İnce contributed to the design, literature search, acquisition and interpretation of the findings, drafted the manuscript, and gave final approval. Erhan Ertekin contributed to the design, critically revised the manuscript, and gave final approval. Raşit Tükel contributed to the design, critically revised the manuscript, and gave final approval. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at https://www.drugsincontext.com/wp-content/uploads/2019/02/dic.212573-COI.pdf

Acknowledgements: None.

Funding declaration: The authors received no financial support for the research, authorship, and publication of this article.

Copyright: Copyright © 2019 Koyuncu A, İnce E, Ertekin E, Tükel R. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2019 Koyuncu A, İnce E, Ertekin E, Tükel R. https://doi.org/10.7573/dic.212573. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://drugsincontext.com/comorbidity-in-social-anxiety-disorder:-diagnostic-and-therapeutic-challenges

Correspondence: Ahmet Koyuncu, Academy Social Phobia Center, Atatürk Mah. İkitelli Cad. No:126 A/Daire:6 Küçükçekmece/Istanbul, Turkey. ahmet_koyu@hotmail.com

Provenance: invited; externally peer reviewed.

Submitted: 1 November 2018; Peer review comments to author: 11 December 2018; Revised manuscript received: 21 February 2019; Accepted: 22 February 2019; Publication date: 2 April 2019.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF